Skip to main content
. 2023 Jan 2;12(1):111. doi: 10.3390/antiox12010111

Figure 2.

Figure 2

Reduced AD neuropathological hallmarks following KYCCSRK intranasal administration in Ts2Cje mice. APP, APP-CTFs, BACE1, TAU and DYRK1A protein levels and phosphorylation were evaluated in the frontal cortex of Eu and Ts2Cje (Ts-V) mice treated with vehicle (saline) and Ts2Cje (Ts-P) treated with KYCCSRK peptide (0.5 mM) for two weeks (n = 4/group). (A) Representative Western blot and total load images and densitometric evaluation of (B–D) APP, -C83 and -C99 fragments protein levels, (E,F) immature (proADAM-10) and mature (mADAM-10) forms of ADAM-10 protein levels, (G) BACE1 protein levels, (H–J) TAU protein levels, AT8 and S404 phosphorylation, and (K) DYRK1A protein levels. All densitometric values were normalized per total protein load and are given as a percentage of Eu set as 100%. In (L,M) BACE1 and DYRK1A mRNA levels are shown. Data are shown as mean ± SEM. One-way ANOVA with Dunnett test: * p < 0.05, ** p < 0.01, *** p < 0.001.